TP ICAP downed by Macquarie, but Exane BNP gives Man Group a lift
A look at some of the top risers and fallers in London in afternoon trading
Company
ReNeuron Group PLC
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 3 of 3
ReNeuron presents more data on potential for its Exosome therapy as cancer treatment
“This work has the potential to uncover a whole new area in cancer therapeutics"
FTSE 100 closes in negative territory as pound strengthens
The FTSE 100 index closed 14.98 down at 7,507, above the day’s low of 7,496.14, and well below the opening high of 7,523.65
Archive
Proactive news snapshot: Synairgen, Silence Therapeutics, LoopUp Group …
A glance at some of the day's highlights from the Proactive Investors newswire
Cyber security firm Shearwater soars as chairman increases holding
Sports Direct, Barratt Developments, Ryanair and EasyJet were among Wednesday's early market movers.
ReNeuron Group's therapeutic programme progressing to plan
In an update ahead of the company’s annual meeting it confirmed it is putting the finishing touches to data packages that will be submitted as part of its application to start a US Phase III clinical trial using its CTX cells to treat strok
Archive
Proactive news snapshot: ITM Power, eg solutions, Haydale Graphene Industries …
A glance at some of the day's highlights from the Proactive Investors newswire
FTSE 100 closes higher despite US jobs data; FTSE 250 lags
London's blue-chip benchmark was holding positive ground, even though US employment figures for August fell short of expectations.
Archive
Proactive news round-up: Sirius Minerals , Seeing Machines, Greatland Gold...
A glance at some of the small cap stories on the Proactive newswire today
London Capital Group shares drop as 2016 results hit by Brexit uncertainty
A look at the biggest risers and fallers of London's small caps
ReNeuron Group upbeat as it progresses on all stem cell fronts
“The unmet medical need in chronic stroke disability is enormous"
Archive
Dixons Carphone still proving resilient on UK High Street
Week ahead: Dixons to show resilience, Bank of England maybe less so
Archive
Proactive end of day round-up: Amur Minerals; 88 Energy; Mosman Oil & Gas ..
A glance at some of the the small cap news on the Proactive newswire today
Fusionex shares rebound amid backlash from Standard Life on plans to cancel AIM listing
A look at the biggest risers and fallers in London today
ReNeuron set the broaden scope of eye disease research after regulatory sign-off for frozen cell line
The US Food & Drug Administration (FDA) green light means its human retinal progenitor cells (hRPC) can be frozen for shipping and storage and thawed at the point of use.
Investments and investor services
FTSE 100 ends higher on day Brexit negotiations begin
The FTSE 100 closed 60 points up at 7,523 as the government begins Brexit negotiations.
Archive
Proactive news round-up: Sirius Minerals, Green Dragon Gas, Reneuron ...
A glance at some of the stories on the Proactive newswire today
Powerhouse Energy energised by up to £500,000 funding deal
Some of the main risers and fallers in London at 3.45pm
ReNeuron Group receives "favourable feedback" and advice on stroke treatment from US regulator
Following “favourable feedback” from the Food & Drug Administration, the watchdog specifically recommended the company apply for a Special Protocol Assessment (SPA) for the phase III study.
FTSE 100 closes in red despite Wall Street gains
The FTSE 100 was subdued in early trade and after the weekend's horrors
Archive
Proactive news round-up: Hayward Tyler, Challenger Acquisition, RM Secured Direct...
A glance at the stories on the Proactive newswire today ..
ReNeuron posts 'very significant' exosome therapy data at Toronto conference
Data shows that ExoPr0 can cross the blood brain barrier and can potentially target multiple diseases via local or systemic administration
Investments and investor services
FTSE 100 closes lower as Trump slump continues
Well, it's not a triple digit fall for the FTSE 100 on Thursday
Global Invacom shares rocket after it posts a swing to a net profit
A look at some of the biggest London-listed risers and fallers today
Reneuron awarded £1.8mln to upgrade Wales facility
The grant will fund key process development activities relating to larger scale commercial manufacture of ReNeuron's cell therapy candidates.
Archive
Proactive news round-up: Kibo Mining; DP Poland, Strategic Minerals...
A reverse takeover of Opera Investments is the method for the deal with the name of the company to be changed to Katoro Gold PLC to reflect the new business focus.
ReNeuron highlights exosome therapy progress at leading conference
Exosome therapy is being explored by ReNeuron both as a potential new nanomedicine targeting cancer and as a delivery system for gene therapy treatments.
Telit Communications shares slip after announcing £39mln cash call
Telit Communications shares have fallen after announcing a fundraising while Diversified Gas & Oil has gained on acquisition news
FTSE 100 rises as US non-farm payrolls report beats expectations
London's top tier index rose 22 points to 7,270.88 at 2.38pm after a better-than-expected US non-farm payrolls report
Archive
Proactive news round-up: Strategic Minerals, MySQUAR, Metal Tiger …
A glance at some of the stories on the Proactive newswire today
MySQUAR shares soar in afternoon deals
A look at some of the hot stocks in early deals on Friday
ReNeuron update outlines ambitious plans for stroke and ophthalmology programmes
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
FTSE 100 ends tough week on a flat note
Friday was a bit of a wash-out, with the Footsie ending little changed after a rough week
Archive
Proactive news round-up: Falcon takes flight
Also featured: AFC, Ferrum Crescent, Galileo, Kibo, Lansdowne Oil, Metal Tiger, Netscientific, Powerhouse, REM, ReNeuron, Tern
ReNeuron makes a guest appearance on BBC2
The cell-based therapeutics group featured in the ‘Andrew Marr: My Brain and Me’ documentary last night
Archive
Proactive News Round-up: Be Heard, LGO Energy, CentralNic ...
A glance at today's headlines on the Proactive newswire …
ReNeuron makes strong start to key trial period
Its strategy is to develop cell lines for "off the-shelf" therapies to treat serious conditions
Archive
Proactive news round-up: Amryt Pharma, Minds+Machines, Aminex ...
A glance at today's headlines on the Proactive newswire
Archive
WEEK AHEAD: The panto season is upon us, and lead villain Mike Ashley is due on stage
He's already told us he's not Santa, but can Mike Ashley deliver a Christmas present for Sports Direct investors?
Are ReNeuron shares ready to explode?
The drifting share price has bottomed out and now represents an “early bird opportunity”, according to Zak Mir
ReNeuron Group PLC's stem cell tech significantly undervalued
“ReNeuron remains well-funded to advance all of its therapeutic programmes through to further significant clinical milestones and we look forward to reporting further progress in the months ahead,” added Hellebø.
ReNeuron Group will hit "milestone" with results next year, says CEO
All patients have now been treated in the PISCES II Phase II clinical trial.
US markets close flat after London rate cut rally fizzles out
After mid-session high, market calms down by end of session
US stock market continues rally after BOE rate cut
Market sees positive activity following unexpected rate cut.
Proactive news highlights: Aminex, Aggregated Micro Power, Magnolia, Metminco and more...
Aggregated Micro Power raises £5mln to fund acquisitions, Metminco firms up terms of the farm-out and Aminex raises a further £1.3mln.
ReNeuron stroke results to be showcased in premier medical journal
We are delighted that the PISCES I clinical trial data has been published in such a prestigious peer reviewed medical journal as The Lancet - Chief executive Olav Hellebø.
Proactive news highlights - Ariana Resources, Cloudbuy, Ferrum Crescent, Kibo Mining and ReNeuron.
NetScientific will deploy its medical tech platform in multiple languages to accommodate multi-cultural clients, Ariana Resources is raising £445,000 to fund exploration drilling and Ferrum Crescent is advancing its Moonlight iron ore proje
ReNeuron unveils positive pre-clinical data from eye trial
The firm recently kicked off a phase I/II clinical trial in the USA and initial short-term safety and tolerability data from the phase I part in the first nine patients is expected in early 2017.
Brexit wrecks it again
FTSE100 shares ended lower on Monday, weighed down by mounting concerns over a possible “Brexit” of the UK from the European Union in a referendum later this month
Investments and investor services
Fitbug catches cold as FTSE 100 Index drops
The FTSE 100 Index fell 51 points to 6065 after the Shanghai Composite closed lower
Risers & Fallers: Ascent Resources, Onzima Ventures, Aveva Group, ReNeuron Group, Egdon Resources, Plutus Powergen
The merger between Aveva Group and Schneider could be back on
ReNeuron completes recruitment for phase II stroke trial
Three-month follow-up data is expected to be available in the fourth quarter of this year.
Proactive news highlights: Deltex, W Resources, Cloudtag and more…
Deltex sings up two new US accounts, W Resources unveils its maiden resource estimate for the São Martinho Gold Deposit, while Cloudtag gets some major retailers on board.
ReNeuron to tackle brain cancer with exosome candidate
Based on promising findings of pre-clinincal models, ReNeuron will be targeting the most common and aggressive form of brain cancer
ReNeuron clinical trial making progress
Researchers at Massachusetts Eye and Ear in Boston are using human retinal progenitor cells (hRPC) to possibly halt the progression of retinitis pigmentosa (RP).
Archive
Proactive news summary: Accesso technology group, Aminex PLC, Green Dragon Gas PLC and more
Horizonte Minerals and its game-changing deal, Chinese Green Dragon subsidy and hefty write-offs for troubled IPSA.
ReNeuron Group PLC treats first patient in retinitis pigmentosa trial
The procedure involves a single injection of hRPC cells under the retina
ReNeuron eyeing data rich period as it progresses four opportunities
Early 2016 looks to be data-rich for stem cell group ReNeuron as it progresses its clinical portfolio on multiple fronts.
Archive
Proactive news summary: dotDigital, Image Scan Holdings, Pan African Resources, TyraTech and more.
Biotech group Scancell is to present an update on its immunotherapy technologies at the Biotech Capital Conference in London.
ReNeuron heads west to find new home in Wales
Stem cell specialist ReNeuron Group will start life in new facilities in Wales next month.
Archive
Proactive news summary: Avation PLC, Premier Oil, OPG Power Ventures and Real Good Food.
A round-up of news from the Proactive Investors universe.
ReNeuron gets notice of US cryptopreservation patent
ReNeuron is using cryopreservation technology in its CTX stem cell line
Archive
FTSE 100 bounces back, with blue-chips leading the way
Unusually, the majority of the big gains today were to be found among the FTSE 350 - especially the FTSE 100
Archive
Proactive news summary: African Potash, Alliance Pharma, Atlantic Coal, Challenger Acquisitions ...
A round-up of the day's company news from the small cap universe
ReNeuron reveals anti-cancer properties of cell line
Researchers found ReNeuron’s specially developed CTX cell line was able to “enrich” a set of these microRNAs with anti-cancer properties.
ReNeuron secures £2.1mln govt grant
The AIM listed biotech is already a world leader in the field and is currently using stems cells to treat stroke patients.
Archive
Proactive news summary: AFC Energy, Atlantis Resources, Brady, Chariot, Forte Energy, Noricum ...
The day's small cap news was dominated by the latest UK oil & gas licensing round.
ReNeuron establishes scientific advisory board
The board’s role is to advise on topics related to ReNeuron’s areas of activity
Investments and investor services
Proactive news highlights: IOG, Motif Bio, allergy Therapeutics, ReNeuron, Immupharma and more
Sunrise Resources, Optibiotix Health and ITM Power also had news out
UPDATE - ReNeuron's third trial gets underway, first in US
Fifteen patients will take part in the trial at the Massachusetts Eye and Ear Infirmary in Boston.
Week Ahead: MPC unlikely to rock the boat
The Bank of England's Monetary Policy Committee is expected to leave its base rate unchanged; the question is, how many committee members will vote for change?
Investments and investor services
Proactive news highlights: Tissue Regenix, ReNeuron, DiamondCorp, Cairn Energy and more
Stratmin Global, Tertiary Minerals and Fastjet also had news out on Friday
ReNeuron adds former Glaxo biotech veteran to board
For many years Dr owen held a research position at the Imperial Cancer Research Fund (now CR-UK).
ReNeuron set for progress over the next three years
Last month the company raised funds which will be used to drive ReNeuron’s existing therapeutic programmes through to 2019.
Investments and investor services
Proactive news summary: ATTRAQT, DekelOil, Magnolia, Mart Resources, Mosman, Mwana, Oilex, Ortac...
Energy firms dominated news flow in the Proactive firmament today
ReNeuron confirms £68.4mln Woodford-backed placing
Lauded fund manager Neil Woodford is among the investors backing the company through the placing.
Risers & Fallers: Mosman, Vedanta, ReNeuron, Macromac, Lonmin, James Fisher and more...
Here are the main news-driven share price movements at 4pm.
Archive
FTSE100 ends higher as new Greek proposal creates optimism
FTSE100 closed out the week over 91 points higher as traders cheered latest moves in Greece.
Archive
Proactive news summary, including fastjet, Hummingbird Resources, Sirius Minerals and Active Energy
A mixed news bag from budget carriers to biotechs..Here are some highlights..
Archive
FTSE 100 celebrates as Greece PM decides game is up
FTSE 100 rose 98 points to 6,680 as Greece PM submitted new debt proposals.
Archive
FTSE 100 surges higher as Greek PM caves in
Tsipras said he had received a mandate in the referendum to negotiate a better deal, not to take the country out of the eurozone.
Investments and investor services
Risers & Fallers: Altona, Igas, ReNeuron, Sefton, Sirius Minerals, Zoltav Resources
It's no surprise that, after two days of stonking gains in Shanghai, Fidelity Special Situations is the best performing FTSE 350 stock.
ReNeuron gets Woodford's backing as it raises £68mln
Olav Hellebø, Renueron’s chief executive, said it is the largest funding by a cell therapy group anywhere this year.
Archive
FTSE100 ends higher as new Greek proposal creates optimism
Investors looked to a brighter future for Greece as its PM Alexis Tsipras submitted a new austerity plan.
Archive
Broker Spotlight – Carnival, SKY, Go-Ahead, Bunzl, Standard Life, Gemfields...
It’ll soon be time for summer holidays, but first City brokers handed out a upgrades in the travel and leisure sector.
Investments and investor services
Proactive news summary: Gemfields, Savannah, ReNeuron, Rambler, Stride, Sierra Rutile and more
It was a busy day in the world of small caps with a lot of companies taming up.
Investments and investor services
Market movers: ReNeuron, Cap-XX, Creightons, Rambler, Gemfields, Styles & Wood
Investors were still buying in after Styles & Wood reported a tripling of underlying profit before tax for 2014 on Friday.
UPDATE - ReNeuron extends collaboration with Australian biotech
ReNeuron's technology appears to offer a delivery mechanism for a gene silencing therapy.
Broker Spotlight – Royal Mail, RBS, Angle Plc, ReNeuron, Sirius Minerals
Here investors can catch up on Thursday's broker views
ReNeuron beefs up management as overseas ambitions grow
Two appointments to strengthen management team as ReNeuron steps up international expansion.
ReNeuron's eye disease treatment placed on fast-track by US regulator
American regulators have recognised the potential ReNeuron’s stem cell treatment for a group of rare eye diseases by granting it fast-track status, according to the company’s chief executive Olav Hellebø.